Research on Amyotrophic Lateral Sclerosis and related conditions
Official title: Clinical Research in Amyotrophic Lateral Sclerosis
Run by University of Miami · NCT00136500 · Data updated 2026-11-12
This study is trying to understand how ALS relates to other nerve diseases and to find new ways to track its progress by looking at people with ALS, those at risk, and healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | University of Miami Academic / other |
| Locations | 1 site (Miami, Florida) |
| Status | Recruiting |
| Started | February 2005 |
| Main results expected | December 2037 |
| Study ends | December 2037 |
| Registry record updated | March 20, 2026 |
| Trial ID | NCT00136500 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with ALS, those at genetic risk for ALS, and healthy controls.
✕Probably not a fit
Patients with other neurological or medical conditions that could confound the study results may not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study, known as CRiALS, aims to recruit participants to explore the complex relationship between Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative disorders. The research focuses on developing biomarkers for ALS and understanding the natural history of the disease from pre-symptomatic stages to late-stage progression. Participants include individuals with ALS, those at genetic risk, and healthy controls, allowing for a comprehensive evaluation of the disease's impact. The study is conducted by the ALS Research Collaboration at the University of Miami.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and early detection of ALS, potentially enhancing patient outcomes.
How similar studies have gone: Other studies have shown promise in understanding ALS through similar observational approaches, indicating potential for meaningful insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. At least 18 years of age. 2. Member of at least one of the following categories: 1. Individuals affected with ALS or a related neurodegenerative disease (sporadic or familial) 2. Unaffected individuals from fALS pedigrees, including pre-symptomatic individuals at genetic risk for ALS or individuals from pedigrees of ALS related diseases. 3. Healthy controls 3. Able and willing to comply with relevant procedures. Exclusion Criteria: 1\. Subject has a condition or is in a situation which, in the PI's opinion, could confound the study finding or may interfere significantly with the individual's participation and compliance with the study protocol -- including but not limited to neurological, psychological and/or medical conditions (e.g., multiple sclerosis, neuropathy, myelopathy).
Where it's running
-
University of Miami
Miami, Florida, United States Recruiting
Study contacts
- Principal investigator: Michael Benatar, MD, PhD. — University of Miami
- Study coordinator: Anne-Laure Grignon, MD
- Email: fals@med.miami.edu
- Phone: 888-413-9315
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Implanted Brain-Computer Interface to Help People with Severe Arm Impairment
We’re testing the N1 System, a fully implanted brain interface in the motor cortex with a robot, to see if it can help adults with spinal cord injury, ALS, or chronic stroke use a computer or keyboard more easily.
-
Brain-computer interface chat tool for people with ALS
This test compares a wearable brain-computer interface communication device to eye-tracking devices that people with ALS currently use to help them communicate.
-
BIIB147 safety and how it behaves in adults with ALS
This study tests BIIB147 in adults with ALS to see if it is safe and how the body handles it, including early and long-term effects.
-
Aims to restore UNC13A function in people with ALS
This trial tests TRCN-1023 in adults with ALS to see if it’s safe, tolerated, and shows early signs of benefit.
-
LTX-002 in adults with ALS
A study will test whether the experimental drug LTX-002 is safe and tolerable in adults with ALS and see how the body handles the drug and how it affects ALS indicators.
-
Repeated ultrasound-assisted blood-brain barrier opening in ALS
This trial tests whether repeatedly opening the blood-brain barrier with ultrasound is safe and may help people with ALS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.